DYN (Dyne Therapeutics) ROCE %: -71.56% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DYN Dyne Therapeutics Inc DYN
34 GF Score
Price $26.50
! 2 Warning Signs
View Full Analysis

What is Dyne Therapeutics ROCE %?

Dyne Therapeutics DYN +0.95% 34 ROCE % is -71.56% as of Jun. 2026. GuruFocus rates DYN with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dyne Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2026 was -71.56%.

Dyne Therapeutics  (NAS:DYN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dyne Therapeutics ROCE % Related Terms

Dyne Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Dyne Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dyne Therapeutics ROCE % Chart

Dyne Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -40.59 -50.64 -120.31 -83.21 -49.29

Dyne Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -64.46 -56.27 -44.77 -43.10 -71.56
DYN
34GF Score
Dyne Therapeutics Inc DYN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dyne Therapeutics ROCE % Calculation

Dyne Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-440.022/( ( (691.234 - 42.258) + (1186.958 - 50.625) )/ 2 )
=-440.022/( (648.976+1136.333)/ 2 )
=-440.022/892.6545
=-49.29 %

Dyne Therapeutics's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-695.844/( ( (1079.95 - 51.249) + (994.013 - 78.029) )/ 2 )
=-695.844/( ( 1028.701 + 915.984 )/ 2 )
=-695.844/972.3425
=-71.56 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -71.56% mean?
Dyne Therapeutics (DYN) has a ROCE % of -71.56% as of Jun. 2026.
Is Dyne Therapeutics' ROCE % too high?
Dyne Therapeutics' current ROCE % is -71.56%. Overall, Dyne Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Dyne Therapeutics' ROCE % compare to VKTX and CELC?
Dyne Therapeutics' ROCE % of -71.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Dyne Therapeutics's current ROCE % is -71.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dyne Therapeutics stock overvalued right now?
Dyne Therapeutics (DYN) has a current ROCE % of -71.56%. The current ROCE % is -71.56%. Dyne Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Dyne Therapeutics (DYN), the current ROCE % is -71.56% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dyne Therapeutics Business Description

Address 1560 Trapelo Road, Waltham, MA, USA, 02451
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
34GF Score

Get the complete analysis for DYN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.50
Price